Leading medical-device companies St. Jude Medical (STJ) and C.R. Bard (BCR) both announced tuck-in acquisitions Monday morning to fill out their product lines.
St. Jude paid $171 million upfront for Switzerland’s Endosense, and could pay up to $161 million more if that firm’s TactiCath ablation catheter meets a regulatory milestone. The device is used in surgeries to treat heart arrhythmias, in which a catheter is fed into the heart.
Bard announced its $200 million buyout of privately held Medafor on Monday. Medafor sells the Arista plant-based hemostat, a device to control bleeding during surgery.